...
首页> 外文期刊>Cell biochemistry and biophysics >Metformin Inhibits Angiogenesis Induced by Interaction of Hepatocellular Carcinoma with Hepatic Stellate Cells
【24h】

Metformin Inhibits Angiogenesis Induced by Interaction of Hepatocellular Carcinoma with Hepatic Stellate Cells

机译:二甲双胍抑制肝癌细胞与肝星状细胞相互作用诱导的血管生成。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Accumulated evidences indicate metformin is associated with reduced risk of hepatocellular carcinoma (HCC) in diabetic patients, which inspired researchers to explore its therapeutic potentials in HCC. Since Hepatic stellate cells (HSCs) are believed to be the key contributors to tumor microenvironment in HCC and promotes tumor development, here, we explored the effect of metformin on tumor angiogenesis induced by interplay of HCC and HSCs. Our results showed that conditional medium from co-culture of HCC/HSCs induced VEGF secretions and stimulated human umbilical vein endothelial cells (HUVEC) tube formation. However, 25 A mu M metformin could inhibit this angiogenesis effect. Furthermore, knockdown AMPK of HSCs, not HCC, could abolish inhibition caused by metformin. Our finding suggested that metformin could inhibit HCC angiogenesis through targeting on HSCs through AMPK pathway.
机译:越来越多的证据表明二甲双胍与糖尿病患者肝细胞癌(HCC)的风险降低有关,这激发了研究人员探索其在HCC中的治疗潜力。由于肝星状细胞(HSC)被认为是HCC肿瘤微环境的主要贡献者,并促进肿瘤的发展,在这里,我们探讨了二甲双胍对HCC和HSC相互作用诱导的肿瘤血管生成的影响。我们的结果表明,HCC / HSCs共培养的条件培养基可诱导VEGF分泌并刺激人脐静脉内皮细胞(HUVEC)管的形成。但是,25 AμM二甲双胍可以抑制这种血管生成作用。此外,敲低HSC而不是HCC的AMPK可以消除由二甲双胍引起的抑制作用。我们的发现表明,二甲双胍可以通过AMPK途径靶向HSC,从而抑制HCC血管生成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号